When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
Verastem (VSTM+5.1%) is up on average volume in apparent response to Genmab's (OTCPK:GNMSF)(OTCPK:GMXAY) failed late-stage study of Arzerra (ofatumumab) in indolent B-cell non-Hodgkin lymphoma. Ofatumumab, a CD-20-directed monoclonal antibody, is currently approved in the U.S. to treat certain patients with chronic lymphocytic leukemia (CLL).
More news on: Verastem, Inc., Genmab A/S, Genmab A/S ADR, Healthcare stocks news, Stocks on the move,